Warfarin (DrugBank: Warfarin)
11 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 2 |
8 | ハンチントン病 | 1 |
13 | 多発性硬化症/視神経脊髄炎 | 1 |
19 | ライソゾーム病 | 1 |
46 | 悪性関節リウマチ | 3 |
49 | 全身性エリテマトーデス | 3 |
66 | IgA腎症 | 3 |
85 | 特発性間質性肺炎 | 1 |
88 | 慢性血栓塞栓性肺高血圧症 | 1 |
96 | クローン病 | 1 |
97 | 潰瘍性大腸炎 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02305030 (ClinicalTrials.gov) | March 2014 | 28/11/2014 | Effect of Opicapone at Steady State on Warfarin Pharmacokinetics | Effect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy Volunteers | Parkinson's Disease | Drug: BIA 9-1067;Drug: Warfarin | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | Both | 20 | Phase 1 | NULL |
2 | NCT02169440 (ClinicalTrials.gov) | June 2009 | 24/1/2012 | Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin | Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers | Parkinson's Disease (PD) | Drug: BIA 9-1067;Drug: Warfarin | Bial - Portela C S.A. | NULL | Completed | 18 Years | 45 Years | All | 20 | Phase 1 | Portugal |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00827034 (ClinicalTrials.gov) | February 2009 | 20/1/2009 | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects | Alzheimer's Disease;Huntington's Disease | Drug: Warfarin;Drug: Dimebon | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | All | 14 | Phase 1 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01462318 (ClinicalTrials.gov) | November 2011 | 14/7/2011 | An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis | A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: Midazolam;Other: Caffeine;Drug: S-warfarin;Other: Vitamin K;Drug: Omeprazole;Drug: Dextromethorphan;Biological: BIIB019 (Daclizumab) | Biogen | NULL | Completed | 18 Years | 65 Years | All | 133 | Phase 3 | United States;Czech Republic;Hungary;Poland;Russian Federation |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00683189 (ClinicalTrials.gov) | June 2007 | 21/5/2008 | Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy | Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy | Metachromatic Leukodystrophy | Drug: Warfarin | The Cooper Health System | NULL | Completed | 1 Year | 10 Years | Both | 10 | N/A | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04246762 (ClinicalTrials.gov) | June 1, 2020 | 27/1/2020 | Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 | A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4 | Rheumatoid Arthritis | Drug: Olokizumab;Drug: Omeprazole;Drug: Caffeine;Drug: Warfarin+ Vitamin K;Drug: Midazolam | R-Pharm | IQVIA RDS Ireland Ltd;Thermo Fisher Scientific | Not yet recruiting | 18 Years | 65 Years | All | 15 | Phase 1 | Bulgaria;Moldova, Republic of |
2 | NCT01636557 (ClinicalTrials.gov) | October 11, 2012 | 6/7/2012 | A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis | A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis | Arthritis, Rheumatoid | Drug: Sirukumab;Drug: Midazolam;Drug: Warfarin;Drug: Vitamin K;Drug: Omeprazole;Drug: Caffeine | Janssen Research & Development, LLC | NULL | Completed | 18 Years | 65 Years | All | 12 | Phase 1 | Germany;Korea, Republic of;Moldova, Republic of;South Africa |
3 | NCT01311622 (ClinicalTrials.gov) | March 2011 | 21/2/2011 | Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects | An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Co-Administered With Fostamatinib in Healthy Subjects | Rheumatoid Arthritis;Healthy Subjects | Drug: warfarin;Drug: fostamatinib | AstraZeneca | NULL | Completed | 18 Years | 55 Years | Both | 15 | Phase 1 | United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03684564 (ClinicalTrials.gov) | September 2020 | 13/8/2018 | RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome | Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open Label, Phase II/III, Non-inferiority Trial | Antiphospholipid Syndrome;Systemic Lupus Erythematosus;Stroke;Ischemic Stroke;Brain Ischemia | Drug: Rivaroxaban;Drug: Warfarin | University College, London | Arthritis Research UK;King's College London;University College London Hospitals;Hammersmith Hospitals NHS Trust;Guy's and St Thomas' NHS Foundation Trust;Barts & The London NHS Trust;King's College Hospital NHS Trust;Manchester University NHS Foundation Trust;Barking, Havering and Redbridge University Hospitals NHS Trust;St George's University Hospitals NHS Foundation Trust | Not yet recruiting | 18 Years | N/A | All | 140 | Phase 2;Phase 3 | NULL |
2 | EUCTR2018-001735-49-GB (EUCTR) | 01/07/2019 | 22/01/2019 | RIvaroxaban for Stroke patients with AntiPhospholipid Syndrome | Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial - RIvaroxaban for Stroke patients with AntiPhospholipid Syndrome | Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE) MedDRA version: 20.0;Level: PT;Classification code 10002817;Term: Antiphospholipid syndrome;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: Rivaroxaban Product Name: Rivaroxaban INN or Proposed INN: Rivaroxaban Other descriptive name: Trade Name Xarelto Trade Name: Warfarin Sodium Product Name: Warfarin Sodium INN or Proposed INN: Warfarin sodium | University College London | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Phase 2;Phase 3 | United Kingdom | ||
3 | EUCTR2012-002345-38-GB (EUCTR) | 30/10/2012 | 08/10/2012 | Comparison of rivaroxaban (Xarelto®; Bayer HealthCare), fixed-dose oral anticoagulant (blood thinner), versus warfarin in patients with antiphospholipid syndrome (called APS), with or without 'lupus' (systemic lupus erythematosus) | A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. - Rivaroxaban in Antiphospholipid Syndrome (RAPS) | Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE). MedDRA version: 14.1;Level: PT;Classification code 10002817;Term: Antiphospholipid syndrome;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | University College London | NULL | Not Recruiting | Female: yes Male: yes | 156 | Phase 2 | United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-C000000363 | 2001/08/01 | 14/05/2007 | A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety | IgA nephropathy in children | prednisolone+mizoribine for 2 years prednisolone+mizoribine+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy ofTreatment Study Group | NULL | Complete: follow-up complete | 2years-old | 18years-old | Male and Female | 80 | Not selected | Japan | |
2 | JPRN-C000000374 | 1998/08/01 | 01/04/2006 | A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children. | IgA nephropathy in children | prednisolone+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy ofTreatment Study Group | NULL | Complete: follow-up complete | 2years-old | 18years-old | Male and Female | 20 | Not selected | Japan | |
3 | JPRN-C000000375 | 1998/08/01 | 01/04/2006 | A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. | IgA nephropathy in children | prednisolone+mizoribine+warfarin+dipyridamole for 2 years | The Japanese Pediatric IgA Nephropathy of Treatment Study Group | NULL | Complete: follow-up complete | 2years-old | 18years-old | Male and Female | 20 | Not selected | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00957242 (ClinicalTrials.gov) | October 2009 | 10/8/2009 | AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis | AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF) | Idiopathic Pulmonary Fibrosis | Drug: warfarin;Drug: placebo | Duke University | National Heart, Lung, and Blood Institute (NHLBI);Duke Clinical Research Institute | Terminated | 35 Years | 80 Years | All | 145 | Phase 3 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000018520 | 2016/01/01 | 01/01/2016 | Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertension | CTEPH (chronic thromboembolic pulmonary hypertension) | Initiation of once-daily Edoxaban(60mg) during 6 months after 2 days discontinuation of warfarin | Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 60 | Phase 4 | Japan |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03358706 (ClinicalTrials.gov) | February 2, 2018 | 27/11/2017 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis. | Crohn Disease;Ulcerative Colitis | Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg | Janssen Research & Development, LLC | NULL | Recruiting | 18 Years | 75 Years | All | 57 | Phase 1 | United States;Belgium;Germany;Sweden;United Kingdom;Austria;Denmark |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03358706 (ClinicalTrials.gov) | February 2, 2018 | 27/11/2017 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis. | Crohn Disease;Ulcerative Colitis | Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg | Janssen Research & Development, LLC | NULL | Recruiting | 18 Years | 75 Years | All | 57 | Phase 1 | United States;Belgium;Germany;Sweden;United Kingdom;Austria;Denmark |